Form 13-F position report

ENZO BIOCHEM INC

Reported by Snowden Capital Advisors LLC

ENZB CUSIP 294100102 Manager CIK 0001903055

Reported 31,704 shares, down 1,350 (4.1%) from the prior quarter.

Reported value 2.9%; share count -4.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2022
Shares 31,704 Quarter-end amount reported
Reported value $70,000 Fair value at quarter end
Consecutive quarters held 17 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 95000
2022-03-31 104000
2022-06-30 68000
2022-09-30 70000
2022-12-31 41619
2023-03-31 54673
2023-06-30 41766
2023-09-30 30099
2023-12-31 28419
2024-03-31 25965
2024-06-30 13129
2024-09-30 11474
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for ENZO BIOCHEM INC held by Snowden Capital Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -10,245 (-100.0%) 0 $0 2025-02-14
Q3 2024 Reduced 10,245 -1,800 (-14.9%) < 0.01% $11,474 2024-11-14
Q2 2024 Reduced 12,045 -8,400 (-41.1%) < 0.01% $13,129 2024-08-14
Q1 2024 Unchanged 20,445 0 (0.0%) < 0.01% $25,965 2024-05-15
Q4 2023 Reduced 20,445 -1,054 (-4.9%) < 0.01% $28,419 2024-02-14
Q3 2023 Reduced 21,499 -1,200 (-5.3%) < 0.01% $30,099 2023-11-14
Q2 2023 Added 22,699 +200 (0.9%) < 0.01% $41,766 2023-08-14
Q1 2023 Reduced 22,499 -6,605 (-22.7%) < 0.01% $54,673 2023-05-15
Q4 2022 Reduced 29,104 -2,600 (-8.2%) < 0.01% $41,619 2023-02-13
Q3 2022 Reduced 31,704 -1,350 (-4.1%) < 0.01% $70,000 2022-11-09
Q2 2022 Reduced 33,054 -3,000 (-8.3%) < 0.01% $68,000 2022-08-12
Q1 2022 Added 36,054 +6,405 (21.6%) < 0.01% $104,000 2022-05-16
Q4 2021 Reduced 29,649 -1,500 (-4.8%) < 0.01% $95,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

51 managers reported ENZO BIOCHEM INC for Q3 2022.

Managers reporting ENZO BIOCHEM INC in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
HARBERT FUND ADVISORS INC Unchanged 5,175,913 0 6.13% $11,542,000 16 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 2,909,664 -106,500 < 0.01% $6,489,000 38 qtrs
Roumell Asset Management LLC Unchanged 2,390,211 0 11.54% $5,330,000 10 qtrs
VANGUARD GROUP INC Unchanged 1,770,749 0 < 0.01% $3,949,000 38 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 1,593,865 -8,510 < 0.01% $3,554,000 38 qtrs
BlackRock Inc Reduced 1,468,121 -62,134 < 0.01% $3,275,000 26 qtrs
FULLER & THALER ASSET MANAGEMENT INC Added 971,010 +13,525 0.02% $2,165,000 6 qtrs
Potomac Capital Management Inc Unchanged 559,500 0 1.43% $1,248,000 4 qtrs
MORGAN STANLEY Reduced 389,198 -31,558 < 0.01% $867,000 38 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 357,544 +977 < 0.01% $797,000 38 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 09, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
31,704
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.